Latest news with #THLPartners
Yahoo
3 days ago
- Business
- Yahoo
THL Partners to acquire clinical trial site company Headlands Research
Private equity company THL Partners has announced its agreement to purchase Headlands Research, a multinational clinical trial sites network, from funds managed by investment company KKR. The transaction is valued at approximately $600m, as per sources who requested anonymity, as reported by Reuters. The alliance is expected to propel Headlands Research's ongoing expansion, with a focus on enhancing its centralised infrastructure and technology. This strategic move is aimed at bolstering Headlands Research's delivery of trial data to biotech and pharma sponsors, supporting the company's aim of progressing medical therapies. Operating across North America, Headlands Research carries out clinical studies in various key therapeutic fields, including vaccines, central nervous system disorders, and metabolic diseases. The company is said to use physician connections and a data-driven operating model, which broadens trial access to traditionally underrepresented subject groups. Headlands was established in 2018 by KKR through its Health Care Strategic Growth Fund to revolutionise the trial site sector and enhance study inclusivity. The investment in Headlands Research will be made through THL's Fund IX, with the transaction's closure anticipated this year, contingent on customary closing conditions. Advising THL on legal matters for the transaction were McDermott Will & Schulte and Paul, Weiss, Rifkind, Wharton & Garrison, with Jefferies serving as the lead financial advisor. Edgemont Partners also provided financial advisory services to THL. KKR and Headlands Research received exclusive financial advice from Houlihan Lokey and legal counsel from Kirkland & Ellis. Headlands Research CEO Kyle Burtnett said: 'I'd like to thank KKR for their tremendous support since our founding. Together, we've built an outstanding business with a highly dedicated team working every day to advance medical research. 'THL shares our vision and excitement for the opportunity to accelerate clinical trial innovation, and we couldn't be more excited to work with their team as we seek to build on the strong foundation that we have in place.' More than 5,000 clinical studies have so far been completed by Headlands Research. Last month, Headlands Research acquired Puerto Rico's clinical research site, CMRCenter, for an undisclosed sum. "THL Partners to acquire clinical trial site company Headlands Research" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
7 days ago
- Business
- Reuters
THL Partners to acquire clinical trial firm Headlands from KKR, sources say
NEW YORK, Aug 14 (Reuters) - Private equity firm THL Partners has agreed to buy a majority stake in Headlands Research, a U.S.-based network of clinical trial sites, from KKR (KKR.N), opens new tab in a deal valued at about $600 million, according to people familiar with the matter. The transaction could be announced as soon as Thursday, the sources said. Clinical trial sites are experiencing steady business growth as pharmaceutical companies ramp up research spending, driven by new types of therapies and the growing healthcare needs of an aging population. Private equity firms have stepped up their involvement in clinical trials, drawn by the potential to leverage technology to scale operations and consolidate a fragmented network of stand-alone sites into more integrated and valuable platforms. THL has been active in pharma services for more than two decades, with past investments including Syneos Health, PCI Pharma Services, Adare Pharma Solutions, and Red Nucleus. The transaction marks an exit for private equity firm KKR, which acquired Headlands in 2018 and is said to have at least doubled its investment, according to a person familiar with the matter. KKR's exit in Headlands followed its successful $12 billion divestment of PRA Health Sciences, a clinical research organization where it delivered a sixfold return for investors. Recent deals by private equity firms in clinical trials include BayPine's $1.5 billion acquisition of CenExel, and Genstar Capital's majority investment in Flourish Research, for an undisclosed amount. AI is accelerating drug discovery and development, and private equity firms are betting that faster approvals of new therapies will boost demand for clinical trials. Headlands operates more than 20 sites and has conducted over 5,000 trials in therapeutic areas including central nervous system disorders, mental health, vaccines, and metabolic diseases.
Yahoo
21-07-2025
- Business
- Yahoo
Inflation impact on business: 'Bigger issue' is customer demand
Inflation concerns linger as economic activity seems to be picking up despite uncertainty around tariffs. Scott Sperling, THL Partners co-CEO, joins Market Catalysts to discuss how tech businesses haven't been severely impacted by inflation but are still remaining cautious about customer demand. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
